TBHQ-tert-Butylhydroquinone-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁
TBHQ-tert-Butylhydroquinone-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁
TBHQ-tert-Butylhydroquinone-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁
TBHQ-tert-Butylhydroquinone-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁
TBHQ-tert-Butylhydroquinone-DataSheet-生命科學(xué)試劑-MedChemExpress_第5頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemETBHQCat.No.:HY-100489CASNo.:1948-33-0Synonyms:tert-Butylhydroquinone分?式:C??H??O?分?量:166.22作?靶點:Keap1-Nrf2;ERK;Autophagy;Apoptosis;Ferroptosis作?通路:NF-κB;MAPK/ERKPathway;StemCell/Wnt;Autophagy;Apoptosis儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:≥56.66mg/mL(340.87mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM6.0161mL30.0806mL60.1612mL5mM1.2032mL6.0161mL12.0322mL10mM0.6016mL3.0081mL6.0161mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;?旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限:-80°C,6months;-20°C,1month。-80°C儲存時,請在6個?內(nèi)使?,-20°C儲存時,請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液,再依次添加助溶劑:(為保證實驗結(jié)果的可靠性,澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實驗的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀1/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(15.04mM);Clearsolution2.請依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(15.04mM);Clearsolution3.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(15.04mM);Clearsolution4.請依序添加每種溶劑:50%PEG300>>50%salineSolubility:20mg/mL(120.32mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性TBHQ(tert-Butylhydroquinone)?種?泛使?的Nrf2激活劑,通過激活Nrf2來免受Doxorubicin(DOX)-誘導(dǎo)的?臟毒性[1]。TBHQ(tert-Butylhydroquinone)也?種ERK激活劑,逆轉(zhuǎn)Dehydrocorydaline(DHC)對?素瘤細(xì)胞增殖的抑制作?[2]。IC50&TargetERKNrf2Autophagy體外研究TBHQ(t-butylhydroquinone;tBHQ;0-100μM;48hours;H9c2cells)alonedoesnotaffectH9c2cellsviability.Pre-incubationoftheH9c2cellswithvariousconcentrationsoftBHQfor24hoursenhancescellviabilitywhichisdecreasedduetoexposuretoethanolinadose-dependentmanner.TreatmentwithtBHQmarkedlyenhancestheviabilityofH9c2cardiomyocytesexposedtoethanol[3].TBHQ(5μM;15min;H9c2cells)treatmentsignificantlyreducestheamountofapoptoticcellsexposedtoethanol[3].TBHQ(5μM;H9c2cells)pre-treatmentmarkedlyinhibitestheethanol-inducedincreaseincaspase-3andBaxexpression,andenhancesBcl-2expression[3].CellViabilityAssay[3]CellLine:H9c2cellsConcentration:0μM,0.625μM,1.25μM,2.5μM,5μM,10μM,20μM,50μMand100μMIncubationTime:48hoursResult:EnhancedtheviabilityofH9c2cardiomyocytesexposedtoethanol.ApoptosisAnalysis[3]CellLine:H9c2cellsConcentration:5μMIncubationTime:Result:Loweredtheamountofapoptoticcellsexposedtoethanol.2/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEWesternBlotAnalysis[3]CellLine:H9c2cellsConcentration:5μMIncubationTime:Result:Inhibitedtheethanol-inducedincreaseincaspase-3andBaxexpression,andenhancedBcl-2expression.體內(nèi)研究TBHQtreatment(50mg/kg;Intraperitonealinjection;threeinjectionsatintervalsof8hthatbegan1-hpostICH;CD-1mice)augmentstheDNA-BindingactivityofNrf2,attenuatesoxidativebraindamageandacuteneurologicaldeficitsafterintracerebralhemorrhage(ICH),attenuatesmicroglialactivationwithconcomitantreductioninthereleaseofproinflammatorycytokineinterleukin-1β(IL-1β).TBHQhastheefficacyofpost-injuryadministrationinattenuatingacuteneurologicalinjuryafterICH[4].AnimalModel:MaleCD-1mice(8-10weeksold)[4]Dosage:50mg/kgAdministration:Intraperitonealinjection;threeinjectionsatintervalsof8hoursthatbegan1hpostICH.Result:ThetreatmentaugmentedtheDNA-bindingactivityofNrf2,attenuatedbrainoxidativedamage,attenuatedthemicroglialactivationandtheexpressionofIL-1β.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?ProcNatlAcadSciUSA.2019Feb19;116(8):2996-3005.?Theranostics.2021Jan1;11(2):861-877.?RedoxBiol.2022Jul31;55:102408.?IntJBiolSci.2022;18(16):6189-6209.?CellDeathDis.2022Aug25;13(8):733.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].Lin-FengWang,etal.Tert-butylhydroquinoneamelioratesdoxorubicin-inducedcardiotoxicitybyactivatingNrf2andinducingtheexpressionofitstargetgenes.AmJTranslRes.2015;7(10):1724–1735.[2].HuH,etal.Dehydrocorydalineinhibitscellproliferation,migrationandinvasionviasuppressingMEK1/2-ERK1/2cascadeinmelanoma.OncoTargetsTher.2019Jul2;12:5163-5175.[3].XIAOJINGSHI,etal.Tert-butylhydroquinoneattenuatestheethanol-inducedapoptosisofandactivatestheNrf2antioxidantdefensepathwayinH9c2cardiomyocytes.IntJMolMed.2016Jul;38(1):123–130.3/4MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[4].Sukumari-RameshS,etal.Post-InjuryAdministrationofTert-butylhydroquinoneAttenuatesAcuteNeurologicalInjuryAfterIntracerebralHemorrhageinMice.JMo

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論